Skip to main content

Advertisement

Springer Nature Link
Log in

Tracer uptake in mediastinal and paraaortal thoracic lymph nodes as a potential pitfall in image interpretation of PSMA ligand PET/CT

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

Since the introduction of 68Ga-PSMA-11 PET/CT for imaging prostate cancer (PC) we have frequently observed mediastinal lymph nodes (LN) showing tracer uptake despite being classified as benign. The aim of this evaluation was to further analyze such LN.

Methods

Two patient groups with biphasic 68Ga-PSMA-11 PET/CT at 1 h and 3 h p.i. were included in this retrospective evaluation. Group A (n = 38) included patients without LN metastases, and group B (n = 43) patients with LN metastases of PC. SUV of mediastinal/paraaortal LN of group A (n = 100) were compared to SUV of LN metastases of group B (n = 91). Additionally, 22 randomly selected mediastinal and paraaortal LN of patients without PC were immunohistochemically (IHC) analyzed for PSMA expression.

Results

In group A, 7/38 patients (18.4%) presented with at least one PSMA-positive mediastinal LN at 1 h p.i. and 3/38 (7.9%) positive LN at 3 h p.i. with a SUVmax of 2.3 ± 0.7 at 1 h p.i. (2.0 ± 0.7 at 3 h p.i.). A total of 11 PSMA-positive mediastinal/paraaortal LN were detected in nine patients considering both imaging timing points. SUVmax of LN-metastases was 12.5 ± 13.2 at 1 h p.i. (15.8 ± 17.0 at 3 h p.i.). SUVmax increased clearly (> 10%) between 1 h and 3 h p.i. in 76.9% of the LN metastases, and decreased significantly in 72.7% of the mediastinal/paraaortal LN. By IHC, PSMA-expression was observed in intranodal vascular endothelia of all investigated LN groups and to differing degrees within germinal centers of 15/22 of them (68.1%). Expression was stronger in mediastinal nodes (p = 0.038) and when follicular hyperplasia was present (p = 0.050).

Conclusion

PSMA-positive mediastinal/paraaortal benign LN were visible in a notable proportion of patients. PSMA-positivity on the histopathological level was associated with the activation state of the LN. However, in contrast to LN metastases of PC, they presented with significantly lower uptake, which, in addition, usually decreased over time.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10

Similar content being viewed by others

References

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. CA Cancer J Clin. 2014;64:9–29.

    Article  PubMed  Google Scholar 

  2. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res. 1994;54:1807–11.

    PubMed  CAS  Google Scholar 

  3. Maresca KP, Hillier SM, Femia FJ, Keith D, Barone C, Joyal JL, et al. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem. 2009;52:347–57.

    Article  PubMed  CAS  Google Scholar 

  4. Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, et al. Preclinical evaluation of novel glutamate–urea–lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009;69:6932–40.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA-ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95.

    Article  PubMed  CAS  Google Scholar 

  6. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA-ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11–20.

    Article  PubMed  CAS  Google Scholar 

  7. Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA-ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197–209.

    Article  PubMed  CAS  Google Scholar 

  8. Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA-ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668–74.

    Article  PubMed  Google Scholar 

  9. Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, et al. Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017:44(8):1258–68.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, et al. Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41:1280–92.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Afshar-Oromieh A, Haberkorn U, Zechmann C, Armor T, Mier W, Spohn F, et al. Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with (131)I-MIP-1095. Eur J Nucl Med Mol Imaging. 2017;44:950–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Chang SS. Overview of prostate-specific membrane antigen. Rev Urol. 2004;6(Suppl 10):S13–8.

    PubMed  PubMed Central  Google Scholar 

  13. Sheikhbahaei S, Afshar-Oromieh A, Eiber M, Solnes LB, Javadi MS, Ross AE, et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging. 2017;44(12):2117–36

    Article  PubMed  Google Scholar 

  14. Krohn T, Verburg FA, Pufe T, Neuhuber W, Vogg A, Heinzel A, et al. 68Ga-PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging. 2015;42:210–4.

    Article  PubMed  Google Scholar 

  15. Afshar-Oromieh A, Hetzheim H, Kübler W, Kratochwil C, Giesel FL, Hope TA, et al. Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging. 2016;43:1611–20.

    Article  PubMed  CAS  Google Scholar 

  16. Eder M, Neels O, Müller M, Bauder-Wüst U, Remde Y, Schäfer M, et al. Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharm Basel Switz. 2014;7:779–96.

    CAS  Google Scholar 

  17. Herrmann K, Bluemel C, Weineisen M, Schottelius M, Wester H-J, Czernin J, et al. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med. 2015;56:855–61.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The theranostic PSMA-ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697–705.

    Article  PubMed  CAS  Google Scholar 

  19. Afshar-Oromieh A, Sattler LP, Mier W, Hadaschik B, Debus J, Holland-Letz T, et al. The clinical impact of additional late PET/CT imaging with 68Ga-PSMA-11 (HBED-CC) in the diagnosis of prostate cancer. J Nucl Med. 2017;58(5):750–755

    Article  PubMed  CAS  Google Scholar 

  20. Sahlmann C-O, Meller B, Bouter C, Ritter CO, Ströbel P, Lotz J, et al. Biphasic 68Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma. Eur J Nucl Med Mol Imaging. 2016;43:898–905.

    Article  PubMed  CAS  Google Scholar 

  21. Wondergem M, van der Zant F, Knol R, Lazarenko S, Pruim J, de Jong IJ. 18F-DCFPyL PET/CT in the detection of prostate cancer at 60 and 120 minutes; detection rate, image quality, activity kinetics and biodistribution. J Nucl Med. 2017;58(11):1797–1804

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

A large number of people helped to plan, investigate, and analyze the patients in past years. Amongst them are (in alphabetic order): Heidrun Adam, Stephanie Biedenstein, Renate Brück, Elena Dahlke, Larissa Engel, Tanja Gerwert, Prof. Frederik Giesel, Daniela Johna, Dr. Christian Kleist, Dr. Susanne Krämer, Dr. Clemens Kratochwil, Kirsten Kunze, Viktoria Reiswich, Franziska Seybold-Epting, Peter Seybold-Epting, Fabian Spohn, and Natalia Zimmermann.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Heidelberg University Hospital, INF 400, 69120, Heidelberg, Germany

    Ali Afshar-Oromieh, Lars Peter Sattler, Walter Mier & Uwe Haberkorn

  2. Department of Nuclear Medicine, Bern University Hospital (Inselspital), Bern, Switzerland

    Ali Afshar-Oromieh & Uwe Haberkorn

  3. Institute of Pathology, Technical University of Munich, Munich, Germany

    Katja Steiger & Wilko Weichert

  4. Department of Biostatistics, German Cancer Research Center, Heidelberg, Germany

    Tim Holland-Letz

  5. Department of Nuclear Medicine, Hospital Israelita Albert-Einstein, São Paulo, Brazil

    Marcelo Livorsi da Cunha

  6. Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany

    Oliver Neels & Klaus Kopka

  7. German Cancer Consortium (DKTK), Heidelberg, Germany

    Oliver Neels & Klaus Kopka

  8. German Cancer Consortium (DKTK), Munich, Germany

    Wilko Weichert

Authors
  1. Ali Afshar-Oromieh
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Lars Peter Sattler
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Katja Steiger
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Tim Holland-Letz
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Marcelo Livorsi da Cunha
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Walter Mier
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. Oliver Neels
    View author publications

    You can also search for this author inPubMed Google Scholar

  8. Klaus Kopka
    View author publications

    You can also search for this author inPubMed Google Scholar

  9. Wilko Weichert
    View author publications

    You can also search for this author inPubMed Google Scholar

  10. Uwe Haberkorn
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Ali Afshar-Oromieh.

Ethics declarations

Ethical approval

All patients published in this manuscript signed a written informed consent form for the purpose of anonymized evaluation and publication of their data. All reported investigations were conducted in accordance with the Helsinki Declaration and with our national regulations (German Medicinal Products Act, AMG §13 2b). This evaluation was approved by the ethics committee of the University of Heidelberg (S-321-2012).

Conflicts of interest

All authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Afshar-Oromieh, A., Sattler, L.P., Steiger, K. et al. Tracer uptake in mediastinal and paraaortal thoracic lymph nodes as a potential pitfall in image interpretation of PSMA ligand PET/CT. Eur J Nucl Med Mol Imaging 45, 1179–1187 (2018). https://doi.org/10.1007/s00259-018-3965-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-018-3965-8

Keywords